127 related articles for article (PubMed ID: 33482231)
1. Inflow-based vascular-space-occupancy (iVASO) might potentially predict IDH mutation status and tumor grade in diffuse cerebral gliomas.
Guo L; Li X; Cao H; Hua J; Mei Y; Pillai JJ; Wu Y
J Neuroradiol; 2022 May; 49(3):267-274. PubMed ID: 33482231
[TBL] [Abstract][Full Text] [Related]
2. Association of Glioma Grading With Inflow-Based Vascular-Space-Occupancy MRI: A Preliminary Study at 3T.
Li X; Liao S; Hua J; Guo L; Wang D; Xiao X; Zhou J; Liu X; Tan Y; Lu L; Xu Y; Wu Y
J Magn Reson Imaging; 2019 Dec; 50(6):1817-1823. PubMed ID: 30932289
[TBL] [Abstract][Full Text] [Related]
3. Noninvasive Assessment of O(6)-Methylguanine-DNA Methyltransferase Promoter Methylation Status in World Health Organization Grade II-IV Glioma Using Histogram Analysis of Inflow-Based Vascular-Space-Occupancy Combined with Structural Magnetic Resonance Imaging.
He W; Li X; Hua J; Liao S; Guo L; Xiao X; Liu X; Zhou J; Wang W; Xu Y; Wu Y
J Magn Reson Imaging; 2021 Jul; 54(1):227-236. PubMed ID: 33590929
[TBL] [Abstract][Full Text] [Related]
4. The Added Value of Inflow-Based Vascular-Space-Occupancy and Diffusion-Weighted Imaging in Preoperative Grading of Gliomas.
Cao H; Xiao X; Hua J; Huang G; He W; Qin J; Wu Y; Li X
Neurodegener Dis; 2020; 20(4):123-130. PubMed ID: 33735873
[TBL] [Abstract][Full Text] [Related]
5. Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma.
Kim M; Jung SY; Park JE; Jo Y; Park SY; Nam SJ; Kim JH; Kim HS
Eur Radiol; 2020 Apr; 30(4):2142-2151. PubMed ID: 31828414
[TBL] [Abstract][Full Text] [Related]
6. Prediction of IDH Mutation Status in High-grade Gliomas Using DWI and High T1-weight DSC-MRI.
Cindil E; Sendur HN; Cerit MN; Erdogan N; Celebi F; Dag N; Celtikci E; Inan A; Oner Y; Tali T
Acad Radiol; 2022 Mar; 29 Suppl 3():S52-S62. PubMed ID: 33685792
[TBL] [Abstract][Full Text] [Related]
7. MR Imaging-derived Oxygen Metabolism and Neovascularization Characterization for Grading and IDH Gene Mutation Detection of Gliomas.
Stadlbauer A; Zimmermann M; Kitzwögerer M; Oberndorfer S; Rössler K; Dörfler A; Buchfelder M; Heinz G
Radiology; 2017 Jun; 283(3):799-809. PubMed ID: 27982759
[TBL] [Abstract][Full Text] [Related]
8. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.
Leu K; Ott GA; Lai A; Nghiemphu PL; Pope WB; Yong WH; Liau LM; Cloughesy TF; Ellingson BM
J Neurooncol; 2017 Aug; 134(1):177-188. PubMed ID: 28547590
[TBL] [Abstract][Full Text] [Related]
9. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.
Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS
Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467
[TBL] [Abstract][Full Text] [Related]
10. Static
Song S; Wang L; Yang H; Shan Y; Cheng Y; Xu L; Dong C; Zhao G; Lu J
Eur Radiol; 2021 Jun; 31(6):4087-4096. PubMed ID: 33211141
[TBL] [Abstract][Full Text] [Related]
11. Glioma grading using multiparametric MRI: head-to-head comparison among dynamic susceptibility contrast, dynamic contrast-enhancement, diffusion-weighted images, and MR spectroscopy.
Seo M; Choi Y; Soo Lee Y; Ahn KJ; Kim BS; Park JS; Jeon SS
Eur J Radiol; 2023 Aug; 165():110888. PubMed ID: 37257338
[TBL] [Abstract][Full Text] [Related]
12. Measurement of arteriolar blood volume in brain tumors using MRI without exogenous contrast agent administration at 7T.
Wu Y; Agarwal S; Jones CK; Webb AG; van Zijl PC; Hua J; Pillai JJ
J Magn Reson Imaging; 2016 Nov; 44(5):1244-1255. PubMed ID: 27028493
[TBL] [Abstract][Full Text] [Related]
13. The role of DSC MR perfusion in predicting IDH mutation and 1p19q codeletion status in gliomas: meta-analysis and technical considerations.
Siakallis L; Topriceanu CC; Panovska-Griffiths J; Bisdas S
Neuroradiology; 2023 Jul; 65(7):1111-1126. PubMed ID: 37173578
[TBL] [Abstract][Full Text] [Related]
14. Application of Distributed Parameter Model to Assessment of Glioma IDH Mutation Status by Dynamic Contrast-Enhanced Magnetic Resonance Imaging.
Li Z; Zhao W; He B; Koh TS; Li Y; Zeng Y; Zhang Z; Zhang J; Hou Z
Contrast Media Mol Imaging; 2020; 2020():8843084. PubMed ID: 33299387
[TBL] [Abstract][Full Text] [Related]
15. On the optimization of 3D inflow-based vascular-space-occupancy (iVASO) MRI for the quantification of arterial cerebral blood volume (CBVa).
Gu C; Li Y; Cao D; Miao X; Paez AG; Sun Y; Cai J; Li W; Li X; Pillai JJ; Earley CJ; van Zijl PCM; Hua J
Magn Reson Med; 2024 May; 91(5):1893-1907. PubMed ID: 38115573
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Immunogenetic Properties of Glial Tumors with Advanced Magnetic Resonance Imaging Findings.
Gezer B; Mutlukan A; Sahinoglu M; Karabagli PN; Koktekir E; Karabagli H
Turk Neurosurg; 2020; 30(3):422-427. PubMed ID: 32091123
[TBL] [Abstract][Full Text] [Related]
17. Amide proton transfer imaging to discriminate between low- and high-grade gliomas: added value to apparent diffusion coefficient and relative cerebral blood volume.
Choi YS; Ahn SS; Lee SK; Chang JH; Kang SG; Kim SH; Zhou J
Eur Radiol; 2017 Aug; 27(8):3181-3189. PubMed ID: 28116517
[TBL] [Abstract][Full Text] [Related]
18. Dynamic contrast-enhanced and dynamic susceptibility contrast perfusion MR imaging for glioma grading: Preliminary comparison of vessel compartment and permeability parameters using hotspot and histogram analysis.
Santarosa C; Castellano A; Conte GM; Cadioli M; Iadanza A; Terreni MR; Franzin A; Bello L; Caulo M; Falini A; Anzalone N
Eur J Radiol; 2016 Jun; 85(6):1147-56. PubMed ID: 27161065
[TBL] [Abstract][Full Text] [Related]
19. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
[TBL] [Abstract][Full Text] [Related]
20. Multiparametric MR-PET measurements in hypermetabolic regions reflect differences in molecular status and tumor grade in treatment-naïve diffuse gliomas.
Tatekawa H; Hagiwara A; Uetani H; Yao J; Oughourlian TC; Bahri S; Wang C; Raymond C; Lai A; Cloughesy TF; Nghiemphu PL; Liau LM; Pope WB; Salamon N; Ellingson BM
J Neurooncol; 2020 Sep; 149(2):337-346. PubMed ID: 32929644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
